Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
Full Year Results 2024
Watch Riad Mishlawi, CEO
Latest stories
Featured
Hikma to host meet the management and site visit in Columbus, Ohio
Press Release, Corporate
17 March 2025
- Hikma announces settlement agreement for Xyrem® (sodium oxybate) U.S. class action lawsuits Press Release, Corporate 08 May 2025 Hikma announces settlement agreement for Xyrem® (sodium oxybate) U.S. class action lawsuits
- S&P upgrades Hikma Pharmaceuticals PLC and its Senior Notes to ‘BBB’ on continued good business momentum; outlook stable Press Release, Corporate 08 May 2025 S&P upgrades Hikma Pharmaceuticals PLC and its Senior Notes to ‘BBB’ on continued good business momentum; outlook stable
- Hikma reiterates full year guidance following good start to the year Press Release, Corporate 24 April 2025 Hikma reiterates full year guidance following good start to the year
- Inspiring women of Hikma - Meet Nesrine Nouhi, General Manager of Hikma France Insight, Life at Hikma 17 April 2025 Inspiring women of Hikma - Meet Nesrine Nouhi, General Manager of Hikma France
